{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:41:10Z","timestamp":1787071270516,"version":"build-2736575974"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Type 2 diabetes mellitus (T2DM) and obesity are commonly treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). However, there have been growing concerns over the possibility that these medications may result in ocular adverse events, such as nonarteritic anterior ischemic optic neuropathy (NAION). Standard clinical care can overlook these potentially fatal adverse effects. The purpose of this review was to compile the most recent data on ocular side effects associated with GLP-1 RA therapy, assess their clinical relevance, and highlight necessary preventative and monitoring measures. A thorough search of the literature was conducted using Medline\/PubMed\/PMC, Google Scholar, Scopus, Web of Science, and ScienceDirect. Relevant literature, including observational studies, randomized trials, case reports, and pharmacovigilance data, was selected for its discussion of GLP-1 RAs and associated eye-related adverse events. Semaglutide, a GLP-1 RA, has been associated in a number of studies and safety assessments with an increased risk of NAION and the progression of diabetic retinopathy, especially in patients with underlying eye disorders. Findings, however, were mixed because no statistically significant link was found in a number of cohort studies and meta-analyses. The necessity for additional research was supported by data from adverse event reporting systems that showed disproportionality signals. Clinicians should be mindful of the potential ocular hazards associated with GLP-1 RAs, even though these medications remain useful in treating T2DM and obesity. Closer ophthalmologic monitoring may be beneficial for patients with known diabetic eye problems. Further prospective research with well-defined ocular outcomes is required to elucidate these correlations and guarantee the secure administration of GLP-1 RAs.<\/jats:p>","DOI":"10.4103\/ijo.ijo_2659_25","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:02:06Z","timestamp":1773331326000},"page":"974-981","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) \u2013 Clinical evidence and insights"],"prefix":"10.4103","volume":"74","author":[{"given":"Naina Mohamed Pakkir","family":"Maideen","sequence":"first","affiliation":[{"name":"Mohammed Bin Rashid University of Medicine and Health Sciences, College of Medicine, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulthan","family":"Al Rashid","sequence":"additional","affiliation":[{"name":"Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Department of Pharmacology, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajkapoor","family":"Balasubramanian","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palanisamy","family":"Amirthalingam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"R1-20260630","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/j.2040-4603.2020.tb00123.x","article-title":"Glucagon-like peptide-1: Actions and influence on pancreatic hormone function","volume":"10","author":"Davis","year":"2020","journal-title":"Compr Physiol"},{"key":"R2-20260630","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.metabol.2019.04.014","article-title":"The incretin system in healthy humans: The role of GIP and GLP-1","volume":"96","author":"Holst","year":"2019","journal-title":"Metabolism"},{"key":"R3-20260630","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"R4-20260630","first-page":"e72080","article-title":"Recent advances and therapeutic benefits of glucagon-like peptide-1 (GLP-1) agonists in the management of type 2 diabetes and associated metabolic disorders","volume":"16","author":"Olukorode","year":"2024","journal-title":"Cureus"},{"key":"R5-20260630","doi-asserted-by":"crossref","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: Beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol"},{"key":"R6-20260630","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"R7-20260630","doi-asserted-by":"crossref","first-page":"6820377","DOI":"10.1155\/2022\/6820377","article-title":"Potential roles of glucagon-like peptide one receptor agonists (GLP-1 RAs) in nondiabetic populations","volume":"2022","author":"Xu","year":"2022","journal-title":"Cardiovasc Ther"},{"key":"R8-20260630","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.JAA.0000669456.13763.bd","article-title":"Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management","volume":"33","author":"Chun","year":"2020","journal-title":"JAAPA"},{"key":"R9-20260630","doi-asserted-by":"crossref","first-page":"51","DOI":"10.15406\/japlr.2019.08.00311","article-title":"Pharmacologically relevant drug interactions of glucagon-like peptide-1 receptor agonists","volume":"8","author":"Maideen","year":"2019","journal-title":"J Anal Pharm Res"},{"key":"R10-20260630","doi-asserted-by":"crossref","first-page":"2042018821997320","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: An updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R11-20260630","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2015","journal-title":"Rev Diabet Stud"},{"key":"R12-20260630","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11938-024-00452-6","article-title":"Glucagon-like peptide 1 receptor agonists for obesity: Efficacy, side effects, and risks","volume":"22","author":"Thota-Kammili","year":"2024","journal-title":"Curr Treat Options Gastroenterol"},{"key":"R13-20260630","doi-asserted-by":"crossref","first-page":"100127","DOI":"10.1016\/j.obpill.2024.100127","article-title":"Glucagon-like receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks","volume":"12","author":"Ghusn","year":"2024","journal-title":"Obesity Pillars"},{"key":"R14-20260630","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/0115748863301925240507044637","article-title":"Suicidal thoughts and self-injurious behavior associated with glucagon-like peptide-1 receptor agonists-A review","volume":"20","author":"Maideen","year":"2024","journal-title":"Curr Drug Saf"},{"key":"R15-20260630","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.3390\/ijerph19052718","article-title":"Efficacy of treatments in nonarteritic ischemic optic neuropathy: A systematic review and meta-analysis","volume":"19","author":"Lantos","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R16-20260630","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/db16-1364","article-title":"GLP-1R as a target for the treatment of diabetic retinopathy: Friend or foe?","volume":"66","author":"Sim\u00f3","year":"2017","journal-title":"Diabetes"},{"key":"R17-20260630","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R18-20260630","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabet.2017.10.014","article-title":"Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes","volume":"44","author":"Feldman-Billard","year":"2018","journal-title":"Diabetes Metab"},{"key":"R19-20260630","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-017-0213-3","article-title":"Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: The synergistic hypothesis","volume":"17","author":"Jingi","year":"2017","journal-title":"BMC Endocr Disord"},{"key":"R20-20260630","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s13167-023-00314-8","article-title":"Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications\u2014risks and mitigation","volume":"14","author":"Kropp","year":"2023","journal-title":"EPMA J"},{"key":"R21-20260630","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ajpath.2024.12.003","article-title":"Characterization and role of glucagon-like peptide 1 receptor in the lacrimal gland: Novel insights into diabetic dry eye pathogenesis","volume":"195","author":"Sun","year":"2025","journal-title":"Am J Pathol"},{"key":"R22-20260630","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/07853890.2022.2157477","article-title":"Dry eye disease: Identification and therapeutic strategies for primary care clinicians and clinical specialists","volume":"55","author":"Sheppard","year":"2023","journal-title":"Ann Med"},{"key":"R23-20260630","article-title":"Ocular effects of GLP-1 receptor agonists: A systematic review of current evidence and safety concerns","author":"Albanese","year":"2025","journal-title":"Preprints"},{"key":"R24-20260630","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12916-025-04031-z","article-title":"Increased vision impairment reports linked to semaglutide: Analysis of FDA adverse event data","volume":"23","author":"Massy","year":"2025","journal-title":"BMC Med"},{"key":"R25-20260630","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12020-024-04112-8","article-title":"Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide one receptor agonists: A pharmacovigilance study based on the FDA adverse event reporting system database","volume":"88","author":"Zhou","year":"2025","journal-title":"Endocrine"},{"key":"R26-20260630","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14740338.2024.2419989","article-title":"Ocular adverse events associated with GLP-1 receptor agonists: A real-world study based on the FAERS database and network pharmacology","volume":"24","author":"Luo","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R27-20260630","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/jamaophthalmol.2025.0349","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes","volume":"143","author":"Hsu","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"R28-20260630","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.orcp.2025.03.001","article-title":"Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?","volume":"19","author":"Procacci","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"R29-20260630","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish\u2013Norwegian cohort study","volume":"27","author":"Simonsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"R30-20260630","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12886-025-03958-4","article-title":"Anterior ischemic optic neuropathy in patients treated with semaglutide: Report of four cases with a possible association","volume":"25","author":"Ahmadi","year":"2025","journal-title":"BMC Ophthalmol"},{"key":"R31-20260630","doi-asserted-by":"crossref","first-page":"33","DOI":"10.33696\/cardiology.6.068","article-title":"Semaglutide-inducing non-arteritic anterior ischemic optic neuropathy and ipsilateral blindness-a rare presentation","volume":"6","author":"Mao","year":"2025","journal-title":"J Clin Cardiol"},{"key":"R32-20260630","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaophthalmol.2024.6058","article-title":"Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide","volume":"143","author":"Katz","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"R33-20260630","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"143","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"R34-20260630","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.orcp.2025.01.011","article-title":"Semaglutide: Nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system\u2013A disproportionality analysis","volume":"19","author":"Azab","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"R35-20260630","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"R36-20260630","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/01658107.2024.2411260","article-title":"Bilateral non-arteritic anterior ischemic optic neuropathy following weight loss from semaglutide (Ozempic): A case report","volume":"49","author":"Karam","year":"2025","journal-title":"Neuroophthalmology"},{"key":"R37-20260630","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"14","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R38-20260630","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/ejhpharm-2024-004333","article-title":"Potential risk of non-arteritic anterior ischaemic optic neuropathy in semaglutide users: Pharmacovigilance insights","volume":"32","author":"Castellana","year":"2025","journal-title":"Eur J Hosp Pharm"},{"key":"R39-20260630","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: A multinational population-based study","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"key":"R40-20260630","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of non-arteritic anterior ischemic optic neuropathy","volume":"274","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R41-20260630","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1177\/19322968241268050","article-title":"Real-world evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"18","author":"Klonoff","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"R42-20260630","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/dom.16076","article-title":"Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials","volume":"27","author":"Silverii","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"R44-20260630","doi-asserted-by":"crossref","first-page":"618353","DOI":"10.3389\/fmed.2021.618353","article-title":"Risk factors for non-arteritic anterior ischemic optic neuropathy: A large-scale meta-analysis","volume":"8","author":"Liu","year":"2021","journal-title":"Front Med"},{"key":"R45-20260630","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17446651.2025.2459720","article-title":"Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: A disproportionality analysis using FDA adverse event reporting system data","author":"Singh","year":"2025","journal-title":"Expert Rev Endocrinol Metab"},{"key":"R46-20260630","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1111\/dom.15788","article-title":"Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A population-based cohort study","volume":"26","author":"Lin","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"R47-20260630","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","article-title":"Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: An aggregated electronic health record data study","volume":"265","author":"Wai","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"R48-20260630","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials","volume":"68","author":"Kapoor","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"R49-20260630","doi-asserted-by":"crossref","first-page":"108255","DOI":"10.1016\/j.jdiacomp.2022.108255","article-title":"Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes\u2013a systematic review and meta-analysis","volume":"36","author":"Yoshida","year":"2022","journal-title":"J Diabetes Complications"},{"key":"R50-20260630","doi-asserted-by":"crossref","first-page":"100547","DOI":"10.1016\/j.xops.2024.100547","article-title":"The effect of glucagon-like peptide-1 receptor agonists on diabetic retinopathy at a tertiary care center","volume":"4","author":"Joo","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"R51-20260630","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.3390\/jcm13206269","article-title":"The effect of glucagon-like-peptide-1 receptor agonists on diabetic retinopathy progression, central subfield thickness, and response to intravitreal injections","volume":"13","author":"Michaeli","year":"2024","journal-title":"J Clin Med"},{"key":"R52-20260630","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/09286586.2024.2399764","article-title":"Glucagon-like peptide-1 receptor agonists are not associated with an increased risk of progressing to vision-threatening diabetic retinopathy","volume":"32","author":"Tauqeer","year":"2025","journal-title":"Ophthalmic Epidemiol"},{"key":"R53-20260630","doi-asserted-by":"crossref","first-page":"103099","DOI":"10.1016\/j.dsx.2024.103099","article-title":"Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: A propensity based cohort study","volume":"18","author":"Yen","year":"2024","journal-title":"Diabetes Metab Syndr"},{"key":"R54-20260630","doi-asserted-by":"crossref","first-page":"100168","DOI":"10.1016\/j.endmts.2024.100168","article-title":"Long-term use of semaglutide and risk of diabetic retinopathy progression","volume":"15","author":"Stevens","year":"2024","journal-title":"Endocr Metab Sci"},{"key":"R55-20260630","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40261-023-01319-x","article-title":"Glucagon-like peptide-1 receptor agonist and risk of diabetic retinopathy in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"43","author":"Jiao","year":"2023","journal-title":"Clin Drug Investig"},{"key":"R56-20260630","doi-asserted-by":"crossref","first-page":"1007980","DOI":"10.3389\/fendo.2022.1007980","article-title":"Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis","volume":"13","author":"Wei","year":"2022","journal-title":"Front Endocrinol"},{"key":"R57-20260630","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","article-title":"Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: An aggregated electronic health record data study","volume":"265","author":"Wai","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"R58-20260630","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00125-024-06132-5","article-title":"Risk of diabetic retinopathy and diabetic macular oedema with sodium\u2013glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: A real-world data study from a global federated database","volume":"67","author":"Eleftheriadou","year":"2024","journal-title":"Diabetologia"},{"key":"R59-20260630","first-page":"290","article-title":"Food and drug administration adverse event reports of diabetic retinopathy, macular edema and blurred vision associated with GLP-1 receptor agonist use","volume":"61","author":"Xiao","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R60-20260630","doi-asserted-by":"crossref","first-page":"108808","DOI":"10.1016\/j.jdiacomp.2024.108808","article-title":"Dipeptidyl peptidase 4 inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists do not worsen diabetic macular edema","volume":"38","author":"Phu","year":"2024","journal-title":"J Diabetes Complications"},{"key":"R61-20260630","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.japh.2023.02.018","article-title":"Vitreous hemorrhage during GLP-1 receptor agonist treatment","volume":"63","author":"Latollari","year":"2023","journal-title":"J Am Pharm Assoc"},{"key":"R62-20260630","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/dom.13484","article-title":"Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis","volume":"21","author":"Avgerinos","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R63-20260630","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/aos.17473","article-title":"Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association","volume":"103","author":"Amini","year":"2025","journal-title":"Acta Ophthalmol"},{"key":"R64-20260630","first-page":"BR35","article-title":"Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation","volume":"17","author":"Xie","year":"2011","journal-title":"Med Sci Monit"},{"key":"R65-20260630","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaophthalmol.2025.1455","article-title":"Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration","volume":"143","author":"Shor","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"Suppl 1","key":"R66-20260630","first-page":"S27","article-title":"Diagnosis and classification of diabetes: Standards of care in diabetes\u20142025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"R68-20260630","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc16-2641","article-title":"Diabetic retinopathy: A position statement by the American Diabetes Association","volume":"40","author":"Solomon","year":"2017","journal-title":"Diabetes Care"},{"key":"R69-20260630","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4103\/ijo.IJO_667_20","article-title":"Diabetic retinopathy screening guidelines in India: All India Ophthalmological Society diabetic retinopathy task force and Vitreoretinal Society of India consensus statement","volume":"69","author":"Raman","year":"2021","journal-title":"Indian J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2659_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:43:56Z","timestamp":1787067836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2659_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2659_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"2024-10-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}